ChromaDex Looks To Pharma Model For Commercializing Supplement Research

Nutritional ingredient developer ChromaDex is employing a pharma-style business model to expand its R&D into finished dietary supplements – with a long-term eye on pharmaceutical products. The firm’s recent hire of CEO Jeffrey Himmel was a significant step into the consumer products arena.

Nutritional ingredient developer ChromaDex Corp. is employing a pharma-style business model to expand its research and development holdings into finished dietary supplements – with a long-term eye on pharmaceutical products.

The Irvine, Calif

More from Clinical Trials

More from R&D